Ron A. M. Fouchier

Ron A. M. Fouchier

Top Cited Scholar 2023
Auto-generated profile, based on publicly available information

Ron A. M. Fouchier

Department of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AZAli M. Zaki
Ali M. Zaki
SBSander van Boheemen
Sander van Boheemen
TBTheo M. Bestebroer
Theo M. Bestebroer
AOAlbert D.M.E. Osterhaus
Albert D.M.E. Osterhaus
RFRon A.M. Fouchier
Ron A.M. Fouchier
A previously unknown coronavirus was isolated from the sputum of a 60-year-old man who presented with acute pneumonia and subsequent renal failure with a fatal outcome in Saudi Arabia. The virus (called HCoV-EMC) replicated readily in cell culture, producing cytopathic effects of rounding, detachment, and syncytium formation. The virus represents a novel betacoronavirus species. The closest known relatives are bat coronaviruses HKU4 and HKU5. Here, the clinical data, virus isolation, and molecular identification are presented. The clinical picture was remarkably similar to that of the severe acute respiratory syndrome (SARS) outbreak in 2003 and reminds us that animal coronaviruses can cause severe disease in humans.

15 May 2003 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
CDChristian Drosten
Christian Drosten
SGStephan Günther
Stephan Günther
Wolfgang PreiserWolfgang Preiser
Wolfgang Preiser
SWSylvie van der Werf
Sylvie van der Werf
HBHans-Reinhard Brodt
Hans-Reinhard Brodt
HDHans Wilhelm Doerr
Hans Wilhelm Doerr
The severe acute respiratory syndrome (SARS) has recently been identified as a new clinical entity. SARS is thought to be caused by an unknown infectious agent. Clinical specimens from patients with SARS were searched for unknown viruses with the use of cell cultures and molecular techniques. A novel coronavirus was identified in patients with SARS. The virus was isolated in cell culture, and a sequence 300 nucleotides in length was obtained by a polymerase-chain-reaction (PCR)–based random-amplification procedure. Genetic characterization indicated that the virus is only distantly related to known coronaviruses (identical in 50 to 60 percent of the nucleotide sequence). On the basis of the obtained sequence, conventional and real-time PCR assays for specific and sensitive detection of the novel virus were established. Virus was detected in a variety of clinical specimens from patients with SARS but not in controls. High concentrations of viral RNA of up to 100 million molecules per milliliter were found in sputum. Viral RNA was also detected at extremely low concentrations in plasma during the acute phase and in feces during the late convalescent phase. Infected patients showed seroconversion on the Vero cells in which the virus was isolated. The novel coronavirus might have a role in causing SARS.

10 July 2009 in Science
Verified
Journal Article
Closed access
PDF file
RGRebecca J. Garten
Rebecca J. Garten
CDC. Todd Davis
C. Todd Davis
CRColin Russell
Colin Russell
BSBo Shu
Bo Shu
SLStephen Lindstrom
Stephen Lindstrom
NCNancy J. Cox
Nancy J. Cox
Generation of Swine Flu: As the newly emerged influenza virus starts its journey to infect the world's human population, the genetic secrets of the 2009 outbreak of swine influenza A(H1N1) are being revealed. In extensive phylogenetic analyses, Garten et al. (p. 197 , published online 22 May) confirm that of the eight elements of the virus, the basic components encoded by the hemagglutinin, nucleoprotein, and nonstructural genes originated in birds and transferred to pigs in 1918. Subsequently, these formed a triple reassortant with the RNA polymerase PB1 that transferred from birds in 1968 to humans and then to pigs in 1998, coupled with RNA polymerases PA and PB2 that transferred from birds to pigs in 1998. The neuraminidase and matrix protein genes that complete the virus came from birds and entered pigs in 1979. The analysis offers insights into drug susceptibility and virulence, as well as raising the possibility of hitherto unknown factors determining host specificity. A significant question is, what is the potential for the H1 component of the current seasonal flu vaccine to act as a booster? Apart from the need for ongoing sequencing to monitor for the emergence of new reassortants, future pig populations need to be closely monitored for emerging influenza viruses.

30 May 2003 in Science
Verified
Journal Article
Open access
PDF file
PRPaul Rota
Paul Rota
MOM. Steven Oberste
M. Steven Oberste
SMStephan S. Monroe
Stephan S. Monroe
WNW. Allan Nix
W. Allan Nix
RCRay Campagnoli
Ray Campagnoli
WBWilliam J. Bellini
William J. Bellini
In March 2003, a novel coronavirus (SARS-CoV) was discovered in association with cases of severe acute respiratorysyndrome (SARS). The sequence of the complete genome of SARS-CoV was determined, and the initial characterization of the viral genome is presented in this report. The genome of SARS-CoV is 29,727 nucleotides in length and has 11 open reading frames, and its genome organization is similar to that of other coronaviruses. Phylogenetic analyses and sequence comparisons showed that SARS-CoV is not closelyrelated to anyof the previouslycharacterized coronaviruses.

16 July 2004 in Science
Verified
Journal Article
Closed access
PDF file
DSDerek Smith
Derek Smith
ALAlan S. Lapedes
Alan S. Lapedes
JJJan C. de Jong
Jan C. de Jong
TBTheo M. Bestebroer
Theo M. Bestebroer
GRGuus F. Rimmelzwaan
Guus F. Rimmelzwaan
RFRon A. M. Fouchier
Ron A. M. Fouchier
The antigenic evolution of influenza A (H3N2) virus was quantified and visualized from its introduction into humans in 1968 to 2003. Although there was remarkable correspondence between antigenic and genetic evolution, significant differences were observed: Antigenic evolution was more punctuated than genetic evolution, and genetic change sometimes had a disproportionately large antigenic effect. The method readily allows monitoring of antigenic differences among vaccine and circulating strains and thus estimation of the effects of vaccination. Further, this approach offers a route to predicting the relative success of emerging strains, which could be achieved by quantifying the combined effects of population level immune escape and viral fitness on strain evolution.

1 June 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BHBernadette G. van Den Hoogen
Bernadette G. van Den Hoogen
JJJan C. de Jong
Jan C. de Jong
JGJan Groen
Jan Groen
TKThijs Kuiken
Thijs Kuiken
RGRonald de Groot
Ronald de Groot
AOAlbert D.M.E. Osterhaus
Albert D.M.E. Osterhaus